Unknown

Dataset Information

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).


ABSTRACT:

Background

Multiple farnesylated proteins are involved in signal transduction in cancer. Farnesyltransferase inhibitors (FTIs) have been developed as a strategy to inhibit the function of these proteins. As FTIs inhibit proliferation of melanoma cell lines, we undertook a study to assess the impact of a FTI in advanced melanoma. As farnesylated proteins are also important for T cell activation, measurement of effects on T cell function was also pursued.

Methods

A 3-stage trial design was developed with a maximum of 40 patients and early stopping if there were no responders in the first 14, or fewer than 2 responders in the first 28 patients. Eligibility included performance status of 0-1, no prior chemotherapy, at most 1 prior immunotherapy, no brain metastases, and presence

SUBMITTER: Gajewski TF 

PROVIDER: S-EPMC3543225 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature